Neil Josephson - Mar 10, 2022 Form 4 Insider Report for Zymeworks Inc. (ZYME)

Role
Chief Medical Officer
Signature
/s/ Daniel Dex, Attorney-in-Fact
Stock symbol
ZYME
Transactions as of
Mar 10, 2022
Transactions value $
$0
Form type
4
Date filed
3/11/2022, 08:00 PM
Previous filing
Jan 11, 2022
Next filing
Jul 5, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZYME Common Shares Options Exercise $0 +729 +10.24% $0.00 7.85K Mar 10, 2022 Direct F1
transaction ZYME Common Shares Options Exercise $0 +1.67K +21.23% $0.00 9.51K Mar 10, 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ZYME Restricted Stock Unit Options Exercise $0 -729 -49.97% $0.00 730 Mar 10, 2022 Common Shares 729 Direct F3, F4
transaction ZYME Restricted Stock Unit Options Exercise $0 -1.67K -33.32% $0.00 3.33K Mar 10, 2022 Common Shares 1.67K Direct F3, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents common shares issued upon vesting of one third of the restricted stock units ("RSUs") granted on March 10, 2020.
F2 Represents common shares issued upon vesting of one third of the RSUs granted on March 10, 2021.
F3 Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock.
F4 The RSUs were granted on March 10, 2020 and vest in three equal annual instalments beginning on March 10, 2021.
F5 The RSUs were granted on March 10, 2021 and vest in three equal annual instalments beginning on March 10, 2022.